Papillary Craniopharyngioma clinical trials at UC Cancer
1 research study open to eligible people
Vemurafenib and Cobimetinib in Treating Patients With BRAF V600E Mutation Positive Craniopharyngioma
open to eligible people ages 18 years and up
This phase II trial studies how well vemurafenib and cobimetinib work in treating patients with BRAF V600E mutation positive craniopharyngioma. Vemurafenib and cobimetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
at UC Irvine
Our lead scientists for Papillary Craniopharyngioma research studies include Yoon Jae Choi.